Health Canada approves GARDASIL for prevention of genital warts in males
July 3rd, 2010
Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by
Pivotal Data Demonstrating Efficacy Of Darusentan In Treating Resistant Hypertension Published In The Lancet
July 1st, 2010
Gilead Sciences, Inc. (Nasdaq:GILD) announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering